Stability of serum concentrations of infliximab and adalimumab across pregnancy in IBD

E. Flanagan*, P. R. Gibson1, A. Ross1, O. Rosella2, S. J. Bell3

1St Vincent’s Hospital, Gastroenterology, Melbourne, Australia, 2Alfred Health, Gastroenterology, Melbourne, Australia, 3Monash University Central Clinical School, Melbourne, Australia

Background: Infliximab (IFX) and adalimumab (ADA) are IgG1 anti-tumour necrosis factor (TNF) monoclonal antibodies, which are transferred across the placenta in the second and third trimesters of pregnancy. There remains a paucity of data relating to maternal serum levels in pregnancy. A small study by Seow et al. observed that IFX levels increased during pregnancy while ADA levels remained stable. However, the sample size and number of intra-partum samples was limited.

Serum trough ADA and IFX were measured in each trimester and at delivery by ELISA (Q-INFLIXI and Q-ADA, Matriks Biotek, Turkey).